JP2023536504A5 - - Google Patents

Info

Publication number
JP2023536504A5
JP2023536504A5 JP2023507923A JP2023507923A JP2023536504A5 JP 2023536504 A5 JP2023536504 A5 JP 2023536504A5 JP 2023507923 A JP2023507923 A JP 2023507923A JP 2023507923 A JP2023507923 A JP 2023507923A JP 2023536504 A5 JP2023536504 A5 JP 2023536504A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
halogen
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023507923A
Other languages
English (en)
Japanese (ja)
Other versions
JP7857914B2 (ja
JP2023536504A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/057089 external-priority patent/WO2022029617A1/en
Publication of JP2023536504A publication Critical patent/JP2023536504A/ja
Publication of JP2023536504A5 publication Critical patent/JP2023536504A5/ja
Priority to JP2026001041A priority Critical patent/JP2026082834A/ja
Application granted granted Critical
Publication of JP7857914B2 publication Critical patent/JP7857914B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023507923A 2020-08-04 2021-08-03 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 Active JP7857914B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026001041A JP2026082834A (ja) 2020-08-04 2026-01-06 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041033326 2020-08-04
IN202041033326 2020-08-04
PCT/IB2021/057089 WO2022029617A1 (en) 2020-08-04 2021-08-03 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026001041A Division JP2026082834A (ja) 2020-08-04 2026-01-06 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物

Publications (3)

Publication Number Publication Date
JP2023536504A JP2023536504A (ja) 2023-08-25
JP2023536504A5 true JP2023536504A5 (cg-RX-API-DMAC7.html) 2024-08-09
JP7857914B2 JP7857914B2 (ja) 2026-05-13

Family

ID=80117730

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023507923A Active JP7857914B2 (ja) 2020-08-04 2021-08-03 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物
JP2026001041A Pending JP2026082834A (ja) 2020-08-04 2026-01-06 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026001041A Pending JP2026082834A (ja) 2020-08-04 2026-01-06 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物

Country Status (11)

Country Link
US (2) US12570650B2 (cg-RX-API-DMAC7.html)
EP (1) EP4192835A4 (cg-RX-API-DMAC7.html)
JP (2) JP7857914B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230061349A (cg-RX-API-DMAC7.html)
CN (1) CN116529250A (cg-RX-API-DMAC7.html)
AU (1) AU2021320052A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002089A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188024A1 (cg-RX-API-DMAC7.html)
IL (1) IL300387A (cg-RX-API-DMAC7.html)
MX (1) MX2023001445A (cg-RX-API-DMAC7.html)
WO (1) WO2022029617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
AU2024348074A1 (en) 2023-09-27 2026-04-30 Haisco Pharmaceutical Group Co., Ltd. Pyrazole carboxylic acid derivative and use thereof in medicine
WO2025196686A1 (en) * 2024-03-20 2025-09-25 Aurigene Oncology Limited Fused bicyclic compounds as smarca2 and/or smarca4 degraders
CN119874808B (zh) * 2025-01-02 2026-04-17 四川大学 一种靶向smarca蛋白降解的化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952188A1 (en) * 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3319944A4 (en) * 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
KR20190140438A (ko) * 2017-02-28 2019-12-19 에피자임, 인코포레이티드 암 치료를 위한 smarca2의 저해
AU2019249849C1 (en) 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
CA3167166A1 (en) * 2020-01-10 2021-07-15 Amgen Inc. Smarca2-vhl degraders

Similar Documents

Publication Publication Date Title
JP2021520372A5 (cg-RX-API-DMAC7.html)
JP2023511471A5 (cg-RX-API-DMAC7.html)
JP2021519783A5 (cg-RX-API-DMAC7.html)
RU2468016C2 (ru) СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl СО СВЯЗЫВАЮЩИМИ ПАРТНЕРАМИ
CN118791506A (zh) Kras抑制剂化合物、其药物组合物及其用途
JP2023511472A5 (cg-RX-API-DMAC7.html)
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
JP2021519308A5 (cg-RX-API-DMAC7.html)
RU2017118453A (ru) Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение
JP2012533570A5 (cg-RX-API-DMAC7.html)
US20130131008A1 (en) Lipophilic monophosphorylated derivatives and nanoparticles
JP2020515571A5 (cg-RX-API-DMAC7.html)
WO2018232725A1 (en) PHARMACEUTICAL COMPOSITIONS
CN109563133A (zh) 多酰胺化合物及其用途
JP6871256B2 (ja) 2−(4−クロロフェニル)−n−((2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン−5−イル)メチル)−2,2−ジフルオロアセトアミドの製剤
KR20140074880A (ko) 암의 치료를 위한 조성물 및 방법
JP2021102616A (ja) 白金耐性の克服における使用のためのテキサフィリン−白金(iv)コンジュゲート及び組成物
JP4852605B2 (ja) 放射線治療増強剤
KR20170118700A (ko) (1e,4e)-2-아미노-n,n-디프로필-8-(4-(피롤리딘-1-카보닐)페닐)-3h-벤조[b]아제핀-4-카복사미드를 포함하는 고체형, 이의 조성물, 및 이의 용도
US11883423B2 (en) Nucleobase analogue derivatives and their applications
JP2023538521A5 (cg-RX-API-DMAC7.html)
EP4244222B1 (en) Succinate and crystal form thereof as therapeutics
KR20120015363A (ko) N-[6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일]-2-메틸-4'-(트리플루오로메톡시)[1,1'-비페닐]-3-카르복스아미드의 염
CA3127502A1 (en) Formulations comprising heterocyclic protein kinase inhibitors
JP2006503079A (ja) 抗癌化合物